| 9.265 2.18 (30.77%) | 10-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.44 | 1-year : | 13.36 |
| Resists | First : | 9.8 | Second : | 11.44 |
| Pivot price | 4.32  |
|||
| Supports | First : | 3.91 | Second : | 0.28 |
| MAs | MA(5) : | 7.01 |
MA(20) : | 3.78 |
| MA(100) : | 2.52 |
MA(250) : | 3.66 |
|
| MACD | MACD : | 1.2 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 77.1 |
D(3) : | 68.3 |
| RSI | RSI(14): 58.5 |
|||
| 52-week | High : | 16.39 | Low : | 0.16 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MBRX ] has closed below upper band by 12.9%. Bollinger Bands are 96.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 31 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.77 - 9.81 | 9.81 - 9.85 |
| Low: | 6.81 - 6.84 | 6.84 - 6.87 |
| Close: | 9.2 - 9.26 | 9.26 - 9.33 |
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
Sun, 25 Oct 2026
Moleculin Biotech (MBRX) Stock Price, News & Analysis - Stock Titan
Fri, 23 Oct 2026
Moleculin Biotech, Inc. Estimates – NASDAQ:MBRX - TradingView
Tue, 20 Oct 2026
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial - GlobeNewswire
Fri, 16 Oct 2026
Half of a 250,000-option grant vests on the grant date at Moleculin Biotech (MBRX). - Stock Titan
Fri, 16 Oct 2026
Moleculin Biotech (MBRX) Announces 1-for-20 Reverse Stock Split Amid Market Selloff - GuruFocus
Fri, 11 Sep 2026
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 838700 (%) |
| Held by Institutions | 7.1 (%) |
| Shares Short | 9 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.883e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -84.6 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 185.82 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 179.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.04 |
| Price to Cash Flow | 0.56 |
| Dividend | 0 |
| Forward Dividend | 10230 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|